Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 7, 2020
Event: Presentation of interim clinical trial data at the Glaucoma 360 Conference.
Key Financial Metrics
This filing is a current report regarding a corporate event (clinical data presentation) and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
The report details interim results from a Phase 1 clinical trial for OTX-TIC, a long-acting travoprost intracameral implant for primary open-angle glaucoma or ocular hypertension.
- Study Design: Prospective, multi-center, open-label, dose escalation trial.
- Cohorts Reported: First two fully-enrolled cohorts (Cohort 1: 5 subjects; Cohort 2: 4 subjects).
- Efficacy: Clinically meaningful reduction in mean intraocular pressure (IOP) at the 8 a.m. timepoint throughout the six-month study period. Reductions persisted beyond the study period, with one patient showing decreased IOP for up to eighteen months.
- Safety: Generally safe and well tolerated. No serious adverse events reported. No changes in corneal health noted.
- Adverse Events: Eight ocular adverse events reported, most frequently iritis.
- Implant Durability: Biodegraded consistently in approximately five to seven months.
Outlook and Management Commentary
Current Status: Enrollment has begun in the third and fourth cohorts of the Phase 1 trial. Continued long-term evaluation is ongoing for the first two cohorts.
Limitations: The Phase 1 trial is not powered to measure efficacy endpoints with statistical significance.
Exhibits: Excerpts from the company presentation containing the data are included as Exhibit 99.1.
Investor Verification Checklist
- Verify the full text of the presentation data in Exhibit 99.1 for detailed statistical breakdowns.
- Monitor the enrollment progress and safety data for the third and fourth cohorts.
- Review subsequent filings for updates on the long-term durability of IOP reduction beyond the initial six-month window.
- Confirm the timeline for potential Phase 2 trial initiation based on these Phase 1 results.